Nortriptyline
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Nortriptyline: From Anxiety Disorder to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Nortriptyline is a tricyclic antidepressant, listed in the knowledge graph for anxiety disorder, neurotic disorder and dysthymic disorder. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), with 0 registered clinical trials and 15 publications (including one RCT in children and a Cochrane review of tricyclics) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorder; neurotic disorder; dysthymic disorder (from the knowledge graph, as the US license records contain no indication text) |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L2 (as assigned in the compiled data; see note below) |
| US Market Status | Cancelled only (no currently valid license) |
| Number of NDAs | 4 (all cancelled ANDA records) |
| Recommended Decision | Proceed with Guardrails |
Note on evidence level: Under the strict rules, L2 requires a completed Phase 2/3 RCT. No trials are registered, but the literature includes a controlled study in children and adolescents (PMID 11052409). The L2 level is therefore provisional and rests on that single publication.
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, nortriptyline is a tricyclic antidepressant that mainly inhibits norepinephrine reuptake and, to a lesser extent, serotonin reuptake. This link is inferred from general knowledge of the drug class, not from the supplied data.
Noradrenergic enhancement in prefrontal circuits is the shared mechanism of established non-stimulant ADHD drugs such as atomoxetine. A PET study in the literature (PMID 24345533) describes nortriptyline as a norepinephrine-transporter-selective tricyclic, which supports this reasoning. Reviews also describe secondary-amine tricyclics, including nortriptyline, as established alternative ADHD treatments.
The original indications (anxiety, neurotic and dysthymic disorders) are psychiatric conditions that often co-occur with ADHD. The high TxGNN score is a computational prediction only and does not replace clinical evidence.
A second predicted entry, ADHD inattentive type (score 99.33%), has no linked trials or literature. It is best treated as a subtype of the parent ADHD indication and reviewed together with it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11052409 | 2000 | RCT | J Child Adolesc Psychopharmacol | Controlled study of nortriptyline’s efficacy and tolerability in children and adolescents with ADHD |
| 25238582 | 2014 | Systematic review (Cochrane) | Cochrane Database Syst Rev | Tricyclic antidepressants as second-line ADHD treatment in children and adolescents |
| 15064003 | 2004 | Review | Psychiatr Clin North Am | Nonstimulant ADHD treatments share noradrenergic/dopaminergic activity. Nortriptyline is an established alternative, but its narrow therapeutic index and cardiovascular toxicity limit use |
| 12270803 | 2002 | Review | Adolesc Med | Overview of ADHD drugs in adolescents, including nortriptyline among the tricyclics |
| 8428873 | 1993 | Clinical study | J Am Acad Child Adolesc Psychiatry | Nortriptyline in children with ADHD and tic disorder or Tourette’s syndrome |
| 8444763 | 1993 | Chart review | J Am Acad Child Adolesc Psychiatry | Chart review of 58 children and adolescents with ADHD treated with nortriptyline |
| 8444754 | 1993 | Retrospective study | J Am Acad Child Adolesc Psychiatry | Serum levels and ECG effects of nortriptyline in children and adolescents |
| 22700161 | 2012 | RCT | Pediatr Nephrol | Randomized double-blind trial of nortriptyline for enuresis in children with ADHD |
| 22303520 | 2012 | Guideline | Ann Clin Psychiatry | CANMAT recommendations for mood disorders with comorbid ADHD |
| 4075308 | 1985 | Clinical study | Clin Neuropharmacol | Early report of nortriptyline in attention deficit disorder |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA073556 | Nortriptyline Hydrochloride (Asclemed USA) | Capsule | Not listed (cancelled) |
| ANDA074132 | Nortriptyline Hydrochloride (Preferred Pharmaceuticals) | Capsule | Not listed (cancelled) |
| ANDA075520 | Nortriptyline Hydrochloride (St. Mary’s Medical Park Pharmacy) | Capsule | Not listed (cancelled) |
| ANDA213441 | Nortriptyline Hydrochloride (Zydus Pharmaceuticals) | Capsule | Not listed (cancelled) |
Safety Considerations
- Contraindications (from the knowledge graph, not label text): long QT syndrome (including familial), torsades de pointes, sudden cardiac arrest, heart conduction disease, myocardial infarction and coronary thrombosis, stroke and cerebrovascular disorders, epilepsy, manic bipolar disorder, open-angle glaucoma and glaucoma, benign prostatic hyperplasia, liver failure, kidney failure and uremia, hyperthyroidism (Graves disease, thyrotoxicosis), substance abuse/dependence, and hemoglobinopathy.
- Drug Interactions: 100 interactions were identified. Major-level examples include epinephrine, bupropion, lorcaserin, potassium citrate and dolasetron. Moderate-level examples include famotidine, cimetidine, clarithromycin, morphine, loperamide and several anticholinergics (atropine, hyoscyamine, glycopyrronium, dicyclomine).
- Literature signals: The ADHD literature highlights the narrow therapeutic index, cardiovascular toxicity (ECG effects) and anticholinergic burden of tricyclics. ECG monitoring and careful co-medication review are advisable.
Please refer to the package insert for the full warnings, as label text was not available.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The literature includes a controlled pediatric study, a Cochrane review of tricyclics and several observational reports supporting nortriptyline in ADHD, with a plausible noradrenergic mechanism. However, no clinical trials are registered, the evidence is mostly older and small-scale, and the cardiac and drug-interaction risks are substantial. No valid US product is currently marketed.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Appraisal of the RCT (PMID 11052409) and the Cochrane review for effect size and safety
- An ECG and serum-level monitoring plan, plus a co-medication review given the large interaction burden
- Regulatory pathway assessment, since all US licenses are cancelled
- Combined review of the ADHD and ADHD inattentive-type entries as one indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.